Ajanta Pharma Ltd 2025 SR
The report is the inaugural GRI-referenced sustainability disclosure for Ajanta Pharma, covering the fiscal year 2024-25. It highlights the company's commitment to environmental, social, and governance pillars across its global specialty pharmaceutical operations. Key achievements include the installation of 12.6 MW of solar capacity, providing 34% of current usage, and recycling 93% of generated waste. The company also emphasizes its R&D focus, with over 550 products launched and a dedicated team of 850+ scientists. Additionally, Ajanta Pharma maintained its 'Great Place to Work' recognition for the third consecutive year.
Company: Ajanta Pharma Ltd
Sector: Health Care
Country: India
Year: 2025
Type: SR
Pages: 27
Ajanta Pharma Ltd
Global Reporting Initiative Report
The report is the inaugural GRI-referenced sustainability disclosure for Ajanta Pharma, covering the fiscal year 2024-25. It highlights the company's commitment to environmental, social, and governance pillars across its global specialty pharmaceutical operations. Key achievements include the installation of 12.6 MW of solar capacity, providing 34% of current usage, and recycling 93% of generated waste. The company also emphasizes its R&D focus, with over 550 products launched and a dedicated team of 850+ scientists. Additionally, Ajanta Pharma maintained its 'Great Place to Work' recognition for the third consecutive year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Renewable Energy
Employees